stockportfolio.pro
Stocks / CORT vs TECH
CORT vs TECH
Corcept Therapeutics Incorporated and Bio-Techne Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
TECH is the larger company ($8.6B vs $8.4B). On the fundamentals, CORT grows revenue faster (16.6% vs 10.5%); CORT earns a higher net margin (12.9% vs 6.0%); CORT has the stronger return on equity (15.2% vs 3.8%). Full numbers below — the stronger figure on each row is in green.
| Corcept Therapeutics Incorporated (CORT) | Bio-Techne Corporation (TECH) | |
|---|---|---|
| Market cap | $8.4B | $8.6B |
| Revenue (latest FY) | $761.41M | $1.22B |
| Net income (latest FY) | $98.17M | $73.40M |
| Revenue growth (5y CAGR) | 16.6% | 10.5% |
| Net margin | 12.9% | 6.0% |
| Return on equity | 15.2% | 3.8% |
| P/E ratio | 222.6 | 78.6 |
| Dividend yield | — | 0.6% |
| Profitable years (of last 10) | 10 | 10 |
| Positive free cash flow | Yes | Yes |
Compare with another company:
See the full CORT vs TECH breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open CORT's full financials → Open TECH's full financials →More comparisons
Frequently asked questions
Which is bigger, CORT or TECH?
Bio-Techne Corporation is larger by market capitalization — $8.6B versus $8.4B.
Which grows faster, CORT or TECH?
Over the last five fiscal years, Corcept Therapeutics Incorporated grew revenue faster — 16.6%/yr versus 10.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.